Fuelled by a visionary leadership team and a diverse, high-caliber Board, PharmaNest is rapidly expanding its circle of passionate scientific and clinical advisors who are accelerating breakthroughs in fibrosis research.
Executive Team
Mathieu Petitjean, Ph.D.
CEO
Mathieu brings over 25 years of global leadership experience in healthcare imaging, diagnostics, and digital innovation, including senior roles at GE Healthcare. With over 50 publications, his work advances AI-driven fibrosis quantification and the standardization of quantitative histopathology.
Li Chen, Ph.D.
Principal Investigator
Li is an experienced pharmaceutical research scientist well-versed in both in-vitro and in-vivo workflows. She leads PharmaNest’s translational studies quantifying fibrosis phenotypes via single-fiber digital pathology and AI analytics
Helene Petitjean, MD
CMO
Helene brings more than two decades of clinical development and strategic leadership in clinical development. Her background spans metabolic and cardiometabolic programs at Bristol Myers Squibb (strategic clinical partnerships), Novo Nordisk (semaglutide cardiovascular trials) , Novartis (Diovan), and Daiichi Sankyo
Offices:
100 Overlook Center, FL2, Princeton, NJ 08540
FibroNest Operations:
We deliver FibroNest worldwide via the Cloud.